Appendix 2

Full-paper screening tool

Escalated dose of imatinib for patients with gastro intestinal stromal tumours

Assessor initials: Date:

Study identifier (Surname of first author + year of publication)	
Type of study Is the study an RCT in which all participants are randomised to imatinib, sunitinib or best supportive care (either provided in addition to imatinib or sunitinib or as only care)? OR Is the study a non-randomised comparative study on patients using either imatinib or sunitinib or best supportive care? OR Is the study case series or case study of more than one patient on same type of diagnosis?	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**
Participants in the study Does the study contain participants with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)? ☐ Unresectable ☐ Metastatic Does the study state that disease has progressed on treatment with imatinib at a dose of 400 mg/day? ☐ Yes ☐ No	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**
Doses and other comparisons Does the study contain at least one group using escalated doses of imatinib (600mg or 800mg per day)? OR Does the study contain at least one group using sunitinib within its recommended dose range (i.e. 25-75 mg/day)? OR Does the study contain at least one group receiving best supportive care	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**
Outcomes reported Does the study report any one of the following outcomes? ☐ Overall response ☐ Overall survival ☐ Disease-free survival ☐ Progression-free survival ☐ Time to treatment failure ☐ Health-related quality of life ☐ Adverse effects of treatment	☐ Yes ☐ Unclear ☐ No ⇩ ⇩ ⇩ Go to next question **Exclude**

Decision	☐ **Include** ☐ **Unclear** ☐ **Exclude** Clarification required